DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2020 của Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies. The Company’s product, Oxecta Tablets CII (Oxecta) represents the immediate-release oxycodone product approved by the United States Food and Drug Administration … More that applies its Aversion Technology. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. As of December 31, 2011, the Company was also developing Nexafed, an over-the-counter (OTC) immediate-release pseudoephedrine HCl tablet, utilizing its Impede Technology. On January 23, 2012, Oxecta was made commercially available by Pfizer Inc. (Pfizer). On June 17, 2011, Oxecta was approved for marketing by the United States Food and Drug Administration.

TÊN CÔNG TY / COMPANY
Acura Pharmaceuticals, Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
ACUR

KỲ BÁO CÁO
2020

NGÀNH / INDUSTRY
Drug Delivery

LĨNH VỰC / SECTOR
Healthcare

LƯU Ý

  • Xin vui lòng đợi một lát để Báo cáo được tải về, tùy thuộc vào dung lượng của Báo cáo mà thời gian có thể nhanh hoặc chậm.
  • Báo cáo chỉ cho phép xem từ Việt Nam.